Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRNA)

IMPORTANT INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

ACCESSWIRE IA May 19, 2020

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire May 19, 2020

Moderna Announces Pricing of Public Offering of Shares of Common Stock

Business Wire May 18, 2020

Moderna Announces Proposed Public Offering of Shares of Common Stock

Business Wire May 18, 2020

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Business Wire May 18, 2020

Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House's Operation Warp Speed Initiative

Business Wire May 15, 2020

Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Business Wire May 12, 2020

Moderna to Present at Upcoming Investor Conferences

Business Wire May 8, 2020

Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates

Business Wire May 7, 2020

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna's Vaccine (mRNA-1273) Against Novel Coronavirus

Business Wire May 1, 2020

Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Business Wire April 27, 2020

Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020

Business Wire April 23, 2020

Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Business Wire April 16, 2020

Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response

PR Newswire April 15, 2020

Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day

Business Wire April 14, 2020

Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format

Business Wire April 10, 2020

Moderna to Present at 19th Annual Needham Healthcare Conference

Business Wire April 8, 2020

Moderna to Host Virtual Vaccines Day on April 14, 2020

Business Wire April 7, 2020

Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development

Business Wire March 29, 2020

Moderna to Present at MIT Lecture Series

Business Wire March 25, 2020